Dyne Therapeutics, Inc. Common Stock

The article compares two clinical-stage biotech companies: Dyne Therapeutics, which targets rare neuromuscular diseases using its FORCE platform, and Viking Therapeutics, which focuses on the larger weight-loss and metabolic disorder market with its VK2735 candidate. Both companies are unprofitable with significant cash burn, but the author recom...

FCPM III Services B.V. reduced its Dyne Therapeutics position by 818,460 shares ($14.11 million) in May 2026, though the fund maintains Dyne as its second-largest holding at 11.8% of assets. Despite the partial exit, the stake reduction appears strategic rather than a loss of conviction, as Dyne shares have surged 56% over the past year. The comp...

DelveInsight's report highlights a robust DMD clinical trial pipeline with 70+ active players developing 75+ pipeline drugs. Key companies including Capricor, Solid Biosciences, Roche, Dyne Therapeutics, and BioMarin Pharmaceutical are advancing promising therapies targeting dystrophin expression and gene transfer. Approximately 6+ drugs are in l...

Saturn V Capital Management sold 822,007 shares of Dyne Therapeutics (worth $14.17 million) in Q1 2026, despite the stock being up 40% over the past year. The fund retained nearly 1 million shares, suggesting a trimming of exposure after the stock's sharp run. Dyne completed a positive pre-BLA meeting with the FDA for z-rostudirsen and remains on...

Dyne Therapeutics has initiated the Phase 3 HARMONIA trial to evaluate z-basivarsen (DYNE-101) in approximately 150 patients with myotonic dystrophy type 1 (DM1). The 48-week randomized, placebo-controlled trial uses the five times sit to stand test as its primary endpoint and is designed to support conversion of Accelerated Approval to tradition...